

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4764099

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	XUANZHU PHARMA CO., LTD.	01/02/2018
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.	
<b>Street Address:</b>	21 FLOOR, BUILDING 2, ZHUBANG 2000 (BUSINESS CENTER)	
<b>Internal Address:</b>	WEST BALIZHUANG, CHAOYANG DISTRICT	
<b>City:</b>	BEIJING	
<b>State/Country:</b>	CHINA	
<b>Postal Code:</b>	100025	
<b>PROPERTY NUMBERS Total: 2</b>		
	<b>Property Type</b>	<b>Number</b>
	<b>Application Number:</b>	15067993
	<b>Application Number:</b>	15383885
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(404)541-3195	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	(404)815-6500	
<b>Email:</b>	sharvey@kilpatricktownsend.com	
<b>Correspondent Name:</b>	KILPATRICK TOWNSEND & STOCKTON LLP	
<b>Address Line 1:</b>	1100 PEACHTREE STREET NE, SUITE 2800	
<b>Address Line 2:</b>	MAILSTOP: IP DOCKETING - 22	
<b>Address Line 4:</b>	ATLANTA, GEORGIA 30309	
<b>ATTORNEY DOCKET NUMBER:</b>	073618-1027059, 1003552	
<b>NAME OF SUBMITTER:</b>	SANDEE HARVEY	
<b>SIGNATURE:</b>	/Sande Harvey/	
<b>DATE SIGNED:</b>	01/08/2018	
<b>Total Attachments: 3</b>		
source=1027059_ASSGNMT#page1.tif		
source=1027059_ASSGNMT#page2.tif		
source=1027059_ASSGNMT#page3.tif		

**ASSIGNMENT**  
(Patent Applications)

This Assignment, effective as of the last execution date written below is made by **XUANZHU PHARMA CO., LTD.**, a corporation of the Peoples Republic of China, having a place of business at 2518 Tianchen Street, National High-Tech Development Zone, Shandong Province, Jinan City, 240101, PRC, hereinafter referred to as "Assignor," to **SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.**, a corporation of the Peoples Republic of China, having a place of business at 21 Floor, Building 2, Zhubang 2000 (Business Center), West Balizhuang, Chaoyang District, Beijing, 100025, PRC, hereinafter referred to as "Assignee."

WHEREAS, Assignor is the owner of all rights, title and interest in certain Patent Applications (as defined below);

WHEREAS, Assignor desires to transfer and Assignee is desirous of acquiring **fifty percent (50%)** of such rights, title, and interest in the Patent Applications;

NOW THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Assignor agrees as follows:

1. Agrees to assign, transfer, convey, and sell; hereby assigns, transfers, conveys and sells; and has assigned, transferred, conveyed, and sold to Assignee **fifty percent (50%)** of the right, title and interest in and to:

(a) the patent applications set forth below:

U.S. Patent Application No.: 15/383,885  
Filed: December 19, 2016  
Title: C-GLYCOSIDE DERIVATIVE  
Attorney Docket No.: 073618-1027059

U.S. Patent Application No.: 15/067,993  
Filed: March 11, 2016  
Title: OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE  
DERIVATIVE  
Attorney Docket No. 073618-1003552

(hereinafter "the Patent Applications") and to intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the Patent Applications, implicitly or explicitly;

- (b) the Patent Applications, the right to claim priority to the Patent Applications, all applications based in whole or in part upon the above-referenced Patent Applications, including, without limitation, all applications that are provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration,

ASSIGNMENT

Attorney Docket Nos. 073618-1027059; 073618-1003552

Page 2 of 3

utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent applications or applications for other rights based in whole or in part on the Patent Applications;

- (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all Patent Applications or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and
  - (d) all claims for damages by reason of past infringement of any rights under (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use;
- 2. Agrees to authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent applications and patents described in Paragraph 1 of this Assignment.
  - 3. Agrees to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
  - 4. Agrees that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successor, assign and other legal representative, and shall be binding upon Assignor, as well as its successor, assign and other legal representative.
  - 5. Promises and affirms that Assignor has not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

XUANZHU PHARMA CO., LTD. (Assignor)

Date: 2018. 1. 2

By:

Chengkon Shih

Name: Chengkon Shih

Title: CEO


ASSIGNMENT

Attorney Docket Nos. 073618-1027059; 073618-1003552

Page 3 of 3

SIHUAN PHARMACEUTICAL  
HOLDINGS GROUP LTD. (Assignee)

Date: 2018. 1. 5

By: 

Name: Fengcheng CHE

Title: President